ArriVent BioPharma, Inc. AVBP Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s investment proceeds?
- ArriVent BioPharma, Inc. (AVBP) reported investment proceeds of $67.97M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s investment proceeds changed year-over-year?
- ArriVent BioPharma, Inc.'s investment proceeds increased by 45.7% year-over-year, from $46.64M to $67.97M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s investment proceeds?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s investment proceeds has grown at a 184.0% compound annual growth rate (CAGR), from $25M to $201.71M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.